Prescient Therapeutics (ASX:PTX) launched a share purchase plan (SPP) to raise up to AU$7 million, with new fully paid ordinary shares to be issued at AU$0.065 per share, according to a Tuesday Australian bourse filing.
The company said the issue price represents an 18.8% discount to the volume-weighted average price over the 10 trading days before the SPP was disclosed and a 9.7% discount to the last price.
The company's shares fell 7% in recent Tuesday trade.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.